糖皮质激素受体表达缺失介导T细胞急性淋巴细胞白血病体内地塞米松耐药
研究对原代小鼠T系急性淋巴细胞白血病(T-ALL)给予地塞米松(DEX)单药或联合pan-PI3K抑制剂GDC-0941治疗,体内持续给药后耐药克隆必然出现,其中约30%克隆的糖皮质激素受体(GR)蛋白表达显著降低,人复发T-ALL中类似比例也呈低GR水平,CRISPR/Cas9证实GR缺失导致DEX耐药。
要点
- 体内持续DEX治疗可筛选出GR蛋白低表达的耐药克隆。
- 约30%的耐药克隆及人复发T-ALL显示GR蛋白水平降低。
- CRISPR/Cas9证实GR表达缺失足以 confer DEX耐药。
核心结论
- GR蛋白表达降低是T-ALL中糖皮质激素耐药的常见原因。
研究设计与样本
- 使用原代小鼠T-ALL模型,体内给予DEX单药或联合GDC-0941治疗。
- 对复发克隆及人复发T-ALL样本进行GR蛋白表达与Nr3c1突变分析。
- 采用CRISPR/Cas9基因编辑验证GR缺失对DEX敏感性的影响。
主要发现
- DEX单药在体内产生强效抗白血病作用,GDC-0941仅轻度增强该效应。
- 体内持续治疗必然导致耐药克隆扩增,其中约30%克隆GR蛋白表达显著降低。
- 人复发T-ALL中类似比例也显示低GR蛋白水平。
- 复发克隆中存在Nr3c1基因的新发或预先存在的突变,来自多个独立亲本白血病。
- CRISPR/Cas9证实GR表达缺失赋予DEX耐药性。
临床怎么用
- T-ALL患者出现糖皮质激素耐药时,可考虑评估GR蛋白表达水平。
- 监测Nr3c1突变可能有助于识别糖皮质激素耐药克隆。
局限性
- 研究主要基于小鼠T-ALL模型,人体T-ALL数据限于复发样本的GR蛋白水平观察。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite decades of clinical use, mechanisms of glucocorticoid resistance are poorly understood. We treated primary murine T lineage acute lymphoblastic leukemias (T-ALLs) with the glucocorticoid dexamethasone (DEX) alone and in combination with the pan-PI3 kinase inhibitor GDC-0941 and observed a robust response to DEX that was modestly enhanced by GDC-0941. Continuous in vivo treatment invariably resulted in outgrowth of drug-resistant clones, ~30% of which showed markedly reduced glucocorticoid receptor (GR) protein expression. A similar proportion of relapsed human T-ALLs also exhibited low GR protein levels. De novo or preexisting mutations in the gene encoding GR (Nr3c1) occurred in relapsed clones derived from multiple independent parental leukemias. CRISPR/Cas9 gene editing confirmed that loss of GR expression confers DEX resistance. Exposing drug-sensitive T-ALLs to DEX in vivo altered transcript levels of multiple genes, and this response was attenuated in relapsed T-ALLs. These data implicate reduced GR protein expression as a frequent cause of glucocorticoid resistance in T-ALL.
引用
- Wandler AM, Huang BJ, Craig JW, et al. Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia. Leukemia. 2020. PMID: 32066867. doi:10.1038/s41375-020-0748-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。